À la une

Actions

Inventiva Explains Why Its Liver Drug Should Work. The Real Test Is Still Ahead

Three conference posters lay out the biology behind lanifibranor, the French biotech's lead drug candidate. They explain the theory; they do not replace the Phase 3 trial results the company expects this quarter.

View through a circle opening at Station La Defense, Paris

Plus d'actualités : France

Décryptages du marché français